~~<i id='E5C8EDF5B3'><strike id='E5C8EDF5B3'><tt id='E5C8EDF5B3'><pre id='E5C8EDF5B3'></pre></tt></strike></i>~~

Home» comprehensive» focus

focus

author：hotspot 2025-09-30 13:04:38 Page View：54

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine
Next article： Medicare proposal to cover medical devices draws a mixed reaction

focus

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Cue Health, Covid

AdobeInanabruptchangeofcoursefromplansearlierinthemonth,at-hometestmakerCueHealthislayingoffallofits

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

H5N1 bird flu outbreak: Second human case reported, in Michigan

MicroscopicimageofH5N1avianinfluenzavirusparticles(inorange).CDCandNIAIDAsecondhumancaseofH5N1birdfl